ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0689

Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment

Blaz Burja1, Paco Welsing2, Alain Lescoat3, Andreas Eisenring4, Anna-Maria Hoffmann-Vold5, Claire Leroy David6, Dinesh Khanna7, Francesco Del Galdo8, Michele Iudici9, Janet Pope10, julia Spierings11, Madelon Vonk12, Marie-Elise Truchetet13, Martine Clergeau14, Michael Hughes15, Susan Murphy16, Tracy Frech17, Oliver Distler18 and Muriel Elhai19, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 2Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, 3CHU Rennes - University Rennes, Rennes, France, 4Patient research partners, Zurich, Switzerland, 5Oslo University Hospital, Oslo, Norway, 6Patient research partners, Sos, France, 7University of Michigan, Ann Arbor, MI, 8University of Leeds, Leeds, United Kingdom, 9Division of Rheumatology, Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland, Geneva, 10University of Western Ontario, London, ON, Canada, 11Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, 12Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Bordeaux University Hospital, Bordeaux, France, 14Patient research partners, Paris, France, 15Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, 16Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Michigan, 17Vanderbilt University Medical Center, Nashville, TN, 18Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 19Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland

Meeting: ACR Convergence 2025

Keywords: Biomarkers, interstitial lung disease, Rheumatoid Factor, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Inflammatory joint and/or tendon involvement affects up to 30% of patients with systemic sclerosis (SSc), resulting in pain, reduced joint function, and impaired patients’ quality of life. The lack of standardized outcome measures for assessing articular activity in SSc hampers therapeutic development and data comparability. To bridge this gap, we aimed to develop a consensus-based composite score to assess articular activity in adult SSc, suitable for research settings and/or clinical practice.

Methods: A steering committee was convened, consisting of 12 rheumatologists, 1 epidemiologist, 1 occupational therapist, and 3 patient research partners. The development of the articular activity score followed a stepwise process (Figure 1). First, a scoping review was conducted using PubMed (January 1960 to April 2023); two reviewers (B.B. and M.E.) independently screened studies on joint/tendon involvement in SSc and extracted assessment tools. Following expert discussions, instruments demonstrating at least 70% validity and feasibility after the committee voting were further evaluated by two independent reviewers according to OMERACT (Outcome Measures in Rheumatology) guidelines. These findings were then presented to the steering committee, and a two-round online Delphi survey was used to finalize the core set.

Results: Of the 770 references initially identified, 658 were excluded based on title or abstract screening, leaving 112 articles for full-text review; ultimately, 86 studies met the inclusion criteria. From these, 46 instruments that were used in at least two studies were identified. Based on domain validity and feasibility, 9 clinical, 1 serological, 3 composite scores, and 3 patient-reported outcome measures were shortlisted for further evaluation (Table 1). Following an assessment of measurement properties according to OMERACT guidelines, the steering committee voted and excluded 10 items due to missing specificity or feasibility on joint activity assessment. 6 final instruments were selected for inclusion in a composite outcome measure to assess articular activity in patients with SSc. The selected instruments covered clinical (28-joint tender/swollen joint count with the addition of distal interphalangeal joints; presence of tendon friction rubs), serologic (CRP) and patient/physician reported outcomes (VAS activity pain patient, VAS activity doctor) domains.

Conclusion: International, multi-disciplinary SSc experts and patient partners have identified 6 feasible core instruments to assess articular activity in SSc patients, covering both joint and tendon involvement. This core set provides the basis to further develop a composite score for articular involvement in SSc for use in clinical practice and clinical trials. Future steps will include performance validation within longitudinal SSc cohorts.

Supporting image 1Figure 1: Scoping review search strategy.

Supporting image 2Table 1: Identified core instruments for assessing disease articular activity in SSc patients. The 28-joint count includes the wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, elbows, shoulders, and knees. The 50-joint count builds on the 28-joint count by also including the distal interphalangeal (DIP) joints, hips, ankles, and metatarsophalangeal (MTP) joints.


Disclosures: B. Burja: None; P. Welsing: None; A. Lescoat: None; A. Eisenring: None; A. Hoffmann-Vold: AbbVie, 2, Avalyn, 2, Boehringer Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard., Bristol-Myers Squibb, 2, Calluna Pharma, 2, Genentech, 2, Janssen, 2, 5, 6, Medscape, 2, 6, Merck Sharp & Dohme, 2, 6, Novartis, 6, Pliant Therapeutics, 2, Roche, 2, 6, Werfen, 2; C. Leroy David: None; D. Khanna: Argenx, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Novartis, 2, UCB, 2, Zura Bio, 2; F. Del Galdo: AbbVie/Abbott, 2, 5, argenx, 2, 5, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Calluna, 2, 5, Deepcure, 2, 5, Engitix, 2, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5, Merck/MSD, 2, 5, Miltenyi, 2, 5, Mitsubishi-Tanabe, 2, 5, Novartis, 2, 5, Ono, 2, 5, Quell, 2, 5, RelationX, 2, 5, Serono, 2, 5, Syntara, 2, 5, Ventus, 2, 5, ZuraBio, 2, 5; M. Iudici: None; J. Pope: AbbVie/Abbott, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, Frese, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Mallinckrodt Pharmaceuticals, 2, 5, Merck/MSD, 2, Mitsubishi Tanabe Pharma, 2, Novartis, 2, Roche, 2, Sandoz, 2, Sanofi, 2, Teva, 2, UCB, 2, Viatris, 2; j. Spierings: None; M. Vonk: Boehringer-Ingelheim, 2, 6, 12, Travel grants, Janssen, 2, 6, 12, travel grants, Merck/MSD, 6; M. Truchetet: AbbVie/Abbott, 2, 12, travel grants, Boehringer-Ingelheim, 2, Eli Lilly, 2, 6, Galapagos, 6, Merck/MSD, 6, Novartis, 6, Pfizer, 2, UCB, 2; M. Clergeau: None; M. Hughes: Janssen, 5, 6, UCB, 5; S. Murphy: None; T. Frech: None; O. Distler: 4P-Pharma, 2, 6, AbbVie/Abbott, 2, 6, Acceleron, 2, 6, Acepodia Biotech, 2, 6, Aera, 2, 6, AnaMar, 2, 6, Anaveon AG, 2, 6, Argenx, 2, 6, AstraZeneca, 2, 6, BMS, 2, 5, 6, Calluna (Arxx), 2, 6, Cantargia AB, 2, 6, CITUS AG, 8, CSL Behring, 2, 6, EMD Serono, 2, 6, Galapagos, 2, 6, Galderma, 2, 6, Gossamer, 2, 6, Hemetron, 2, 5, 6, Innovaderm, 2, 5, 6, Janssen, 2, 6, Mediar, 2, 5, 6, mir-29 for the treatment of systemic sclerosis, 10, Mitsubishi Tanabe, 2, 5, 6, MSD Merck, 2, 6, Nkarta Inc., 2, 6, Novartis, 2, 6, Orion, 2, 6, Pilan, 2, 6, Prometheus, 2, 6, Quell, 2, 6, Sumitomo, 2, 5, 6, Topadur, 2, 5, 6, UCB, 2, 5, 6; M. Elhai: AstraZeneca, 12, Congress support, Boehringer-Ingelheim, 6, FOREUM, 5, Iten Kohaut foundation, 5, Janssen, 12, Congress support, Kurt und Senta Herrmann foundation, 5, Novartis, 5, Pfizer, 5, University Zurich, 5.

To cite this abstract in AMA style:

Burja B, Welsing P, Lescoat A, Eisenring A, Hoffmann-Vold A, Leroy David C, Khanna D, Del Galdo F, Iudici M, Pope J, Spierings j, Vonk M, Truchetet M, Clergeau M, Hughes M, Murphy S, Frech T, Distler O, Elhai M. Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/development-of-an-articular-activity-score-in-systemic-sclerosis-assess-identifying-core-instruments-for-disease-activity-assessment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-an-articular-activity-score-in-systemic-sclerosis-assess-identifying-core-instruments-for-disease-activity-assessment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology